Cagrilintide is a dual amylin/calcitonin receptor agonist that is currently in clinical development. About Viking Therapeutics, Inc. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical ...

Viking Therapeutics highlighted new clinical data ... Structure Therapeutics selected ACCG-2671 as its lead oral small molecule amylin receptor agonist for obesity and related diseases.

Viking Therapeutics (NASDAQ ... The company is also conducting preclinical studies on a series of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic disorders ...

Shares of Viking Therapeutics, Inc. (NASDAQ ... announced plans to submit an IND to start a phase 1 trial of the novel amylin agonist candidate, on which it presented positive preclinical data ...

Pills that work similarly to currently available injectable medications represent the next wave of metabolic disorder drugs, and Viking Therapeutics is pushing its drug candidate to the forefront ...

About Viking Therapeutics, Inc. Viking Therapeutics ... newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment ...

Highlights from poster 2024-LB-5842: Novel Amylin and Calcitonin Receptor Co-Agonists Reduce Food Intake and Body Weight in Rodents. Viking DACRAs demonstrated EC50 values ranging from low nM to ...

Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO, June 24, 2024 ...